Paratek Pharmaceuticals (FRA:N4CN) YoY EBITDA Growth : 35.93% (As of Jun. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Paratek Pharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Paratek Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Jun. 2023 was 35.93%.

Paratek Pharmaceuticals's EBITDA per Share for the three months ended in Jun. 2023 was €-0.15.

Paratek Pharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for Paratek Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals YoY EBITDA Growth Chart

Paratek Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

YoY EBITDA Growth

Get a 7-Day Free Trial

-8.99

-9.31

54.19

47.20

-4.70

Paratek Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
YoY EBITDA Growth	Get a 7-Day Free Trial															-196.25	-25.32	91.16	-10.39	35.93

Paratek Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Paratek Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Dec. 2022 is calculated as:

	YoY EBITDA Growth (A: Dec. 2022 )
=	(EBITDA per Share (A: Dec. 2022 )	-	EBITDA per Share (A: Dec. 2021 ))	/	\| EBITDA per Share (A: Dec. 2021 ) \|
=	(-0.779	-	-0.744)	/	\| -0.744 \|
=	-4.70 %

Paratek Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Jun. 2023 is calculated as:

	YoY EBITDA Growth (Q: Jun. 2023 )
=	(EBITDA per Share (Q: Jun. 2023 )	-	EBITDA per Share (Q: Jun. 2022 ))	/	\| EBITDA per Share (Q: Jun. 2022 )) \|
=	(-0.148	-	-0.231)	/	\| -0.231 \|
=	35.93 %

Paratek Pharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Paratek Pharmaceuticals (FRA:N4CN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (FRA:N4CN) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 Park Plaza, 4th Floor, Boston, MA, USA, 02116

Website

https://www.paratekpharma.com

Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Paratek Pharmaceuticals (FRA:N4CN) Headlines

No Headlines